This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $7.68, moving -0.13% from the previous trading session.
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
by Kinjel Shah
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
Teva Pharmaceutical Industries Ltd. (TEVA) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.11 in the latest trading session, marking a -1.1% move from the prior day.
Teva Shares Fall Further as Morgan Stanley Downgrades Rating
by Zacks Equity Research
Shares of Teva (TEVA) are on a downtrend on the risk of high litigation costs related to opioid epidemic in the United States. Morgan Stanley downgrades its rating on Teva.
J&J (JNJ) Beats on Q2 Earnings, Ups 2019 Sales Growth View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the second quarter of 2019 and raises 2019 guidance for operational sales growth for the second time this year.
Amneal (AMRX) Down on Guidance Update & Restructuring Plan
by Zacks Equity Research
Amneal (AMRX) slumps on news of budget cut and reduction in annual guidance.
Court Ruling Topples Trump Order, No Price Display in TV Ads
by Zacks Equity Research
The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.
Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
by Zacks Equity Research
Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.
Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.43 in the latest trading session, marking a +1.18% move from the prior day.
Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer
by Zacks Equity Research
Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.
AstraZeneca Gets CHMP Nod for Forxiga/Fasenra Expanded Label
by Zacks Equity Research
AstraZeneca (AZN) gets positive CHMP opinion for self-administration option for Fasenra and the Fasenra pen and to include outcomes data on Forxiga???s label.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.89 in the latest trading session, marking a +0.91% move from the prior day.
Allergan's Botox Wins FDA Nod for Upper Limb Spasticity in Kids
by Zacks Equity Research
Allergan's (AGN) Botox gets FDA approval for the 10th therapeutic indication, upper limb spasticity in pediatric patients, in the age group of 2 to 17 years.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.12 in the latest trading session, marking a -0.73% move from the prior day.
Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
by Zacks Equity Research
Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $8.62 in the latest trading session, marking a -1.03% move from the prior day.
Teva Pharmaceutical Industries Ltd. (TEVA) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $9.26 in the latest trading session, marking a -1.59% move from the prior day.
Celgene's Filing for Ozanimod Accepted for Review in US/EU
by Zacks Equity Research
The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.
Lilly's Emgality Gets FDA Approval for Cluster Headache
by Zacks Equity Research
Lilly's (LLY) CGRP antibody, Emgality, becomes the first and only medicine approved to treat episodic cluster headache in adults.
Biogen Reports Interim Phase III Data on Diroximel Fumarate
by Zacks Equity Research
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Lilly In-Licenses Private Biotech's Non-Opoid Pain Candidate
by Zacks Equity Research
Lilly (LLY) inks a deal with the privately held Centrexion Therapeutics to add the latter's early-stage pain candidate, CNTX-0290, to its portfolio.
Teva Settles With Oklahoma, Shares Fall Following Downgrade
by Zacks Equity Research
Teva (TEVA) plummets after settlement with the state of Oklahoma in a litigation related to its role in opioid epidemic, resulting in a rating downgrade.
Company News For May 29, 2019
by Zacks Equity Research
Companies in the news are: UBER, TEVA, AMD and ASGN
Roche Gets FDA Nod for Venclexta Plus Gazyva to Treat CLL
by Zacks Equity Research
Roche (RHHBY) gains an FDA nod for the sNDA of its leukemia drug, Venclexta, in combination with Gazyva for the treatment of previously untreated chronic lymphocytic leukemia.
The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer